Current evidence indicates cardio‐metabolic effects from antithyroid drugs and other definitive treatment options for hyperthyroidism. The EGRET study aimed to assess the differences in mortality and cardiometabolic outcomes depending on the method of treatment in order to better inform patient‐clinician decision‐making. In this touchENDOCRINOLOGY interview, Prof. Kristien Boelaert (University of Birmingham, Birmingham, United Kingdom) discusses the aims, design, eligibility criteria and the findings of the EGRET study as well as how these findings be used to inform future treatment decisions.
The abstract entitled: ‘LONG‐TERM MORTALITY AND CARDIOMETABOLIC EFFECTS OF TREATMENT FOR HYPERTHYROIDISM: EGRET STUDY‘ was presented at the American Thyroid Association Annual Meeting, 19-23 Oct, 2022.
Questions:
- What were the aims, design and eligibility criteria of the EGRET study? (0:15)
- What were the findings in terms of mortality, MACE and weight gain? (2:05)
- How will these findings be used to inform future treatment decisions? (3:51)
Disclosures: Kristien Boelaert has nothing to disclose in relation to this video interview.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of ATA 2022
